Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Prepared Remarks Transcript

Qiagen (QGEN) reported robust Q1 and Q2 growth of 7% and 6% respectively, outperforming peers and leading to increased revenue and EPS guidance. The company highlighted continued double-digit growth in its QuantiFERON franchise and strong QIAstat placements, bolstered by recent FDA approvals. Upcoming product launches in sample prep, including Symphony Connect and QIAsprint, are expected to drive future growth and market share expansion. Despite challenges in the U.S. academic instrumentation market and double-digit declines in China, Qiagen anticipates reaching its 31% adjusted operating margin target by 2026, ahead of schedule, driven by efficiency gains and improved utilization, while maintaining a balanced capital allocation strategy.

Analysis

Qiagen N.V. (QGEN) demonstrated strong fundamental performance in the first half of the year, with revenue growth of 7% in Q1 and 6% in Q2, approximately double the rate of the diversified tools sector. This outperformance in a challenging macroeconomic environment prompted an increase in both its full-year revenue and EPS guidance. A key driver remains the QuantiFERON franchise, which has posted over 20 consecutive quarters of double-digit growth and continues to benefit from a significant market penetration opportunity, as 60-65% of the latent TB testing market still relies on a 120-year-old skin test. The QIAstat syndromic testing platform is also a major contributor, with 30% growth last quarter and expectations for continued double-digit expansion, bolstered by recent FDA approvals that now allow it to compete in the U.S. tender-based market. While current sample prep growth is modest, the company is poised for acceleration with three new instrument launches planned for late 2025 and 2026, including the QIAsprint system, which will provide entry into the high-throughput segment where Qiagen currently has no footprint. Management noted contained headwinds from a soft U.S. academic instrumentation market (affecting ~6% of revenue) and a double-digit decline in China (4-5% of revenue), but expects to reach its 31% adjusted operating margin target by 2026, two years ahead of schedule, driven by efficiency programs and improved asset utilization.

Key Decisions for Investors

• Investors should note that Qiagen is on an accelerated timeline to achieve its 31% adjusted operating margin target by 2026, well ahead of the initial 2028 goal, signaling strong operational leverage and profitability improvement.
• The upcoming product cycle in the sample preparation business, with three new platforms launching through 2026 including the QIAsprint system, represents a significant catalyst for growth re-acceleration in a core franchise.
• While the company's overall outlook is positive, it is prudent to monitor the persistent weakness in the U.S. academic market and the ongoing declines in China, as these represent the primary, albeit contained, headwinds to the growth narrative.
• Consider the durability of the QuantiFERON franchise, as its leading market position is reinforced by a competitor's delayed U.S. launch and a large, underpenetrated market that provides a long runway for sustained double-digit growth.